VOYAGER DEMONSTRATES SINGLE IV DOSE OF VY1706 WELL TOLERATED, REDUCED TAU IN 6-MONTH GLP TOXICOLOGY STUDY; INITIATION OF CLINICAL TRIAL IN ALZHEIMER’S DISEASE EXPECTED H2 2026

Reuters · 1d ago

Please log in to view news